An observational study in Cardiac Output, Low, Cardiac Output, High and Congestive Heart Failure, sponsored by Biobeat Technologies Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Biobeat Technologies Ltd. · Observational
Invasive pulmonary capillary wedge pressure measurements using a Swan-Ganz catheter (SGC) is considered the gold standard for cardiac output (CO) monitoring. In this prospective study, we will compare CO measurements between a PPG-based wearable monitor and a SGC in ambulatory CHF patients.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 100 is below the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Biobeat Technologies Ltd. is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients from both sexes with CHF arriving for an ambulatory assessment using a Swan-Ganz catheter in the Medical Center's Cath-lab.
Exclusion Criteria:
non-invasive measurements of cardiac output
Comparison of cardiac output obtained by a non-unvasive device to the invasive method
In each participant, a Swan-Ganz catheter will be inserted as part of their routine assessment, and cardiac output measurements will be compared with a non-invasive wearable and wireless PPG-based device.
Time frame: 2-4 hours per patient
Plan to share: Undecided — We aim to publish the results of this study in a peer-reviewed journal.
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biobeat Technologies Ltd.